Takeda files NDA for antibiotic drug in Japan

Takeda Pharmaceutical Company has filed a new drug application to the Ministry of Health, Labour and Welfare for Lampion for treatment of secondary eradication of Helicobacter pylori.

According to Takeda, Lampion is a single pack containing lansoprazole, amoxicillin and metronidazole. A triple therapy with a producer price index, amoxicillin and clarithromycin is the standard treatment of first eradication of H Pylori for gastric ulcers or duodenal ulcers in Japan.

In cases where H Pylori is still not eradicated with this treatment, a triple therapy regimen, replacing clarithromycin with metronidazole was approved in August 2007 in Japan.

Lampion contains all three drugs required to be taken each day and provides better compliance for treatment of secondary eradication, which is expected to increase efficacy for secondary eradication of H Pylori.

In addition to currently available Lansap for treatment of first eradication of H Pylori, Lampion for treatment of second eradication of H Pylori is expected to provide a meaningful contribution to eradication therapy for patients and healthcare professionals, the company said.

Takeda is a research-based global pharmaceutical company. Takeda is enhancing its R&D pipeline by concentrating its management resources. Takeda’s ethical drugs are marketed in around 90 countries worldwide and are recognized as the brand in major countries worldwide.